Rouannet et al12 reported the 10‐year prognosis of patients with HER2‐positive tumors was worse than HER2‐negative (disease‐free survival 73% vs 89%), while tumor size (T1a/T1b) was not a relevant prognostic factor. This evidence concerns the gene ERBB2 and neoplasm.